{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-027106","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2025-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.429115+00:00","generated_at":"2026-05-24T00:54:43.090970+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"INmune Bio presents MINDFuL Phase II baseline data at AD/PD 2025; topline results due June 2025","bullets":["Poster details baseline demographics of 208 patients (44% MCI, 56% mild AD) enrolled in MINDFuL Phase II trial of XPro1595.","69.2% of patients are APOE ε4 carriers; 64.4% met inclusion criteria for more than one inflammation biomarker.","Primary endpoint is change from baseline in Early and Mild Alzheimer's Cognitive Composite (EMACC) score; topline results expected June 2025.","Patients randomized 2:1 to XPro 1.0 mg/kg or placebo once weekly for 23 weeks; screen failure rate was 72%.","Baseline characteristics show similarity to Phase III trials; no efficacy data disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-027106","json":"https://secwatch.observer/filing/0001213900-25-027106.json","markdown":"https://secwatch.observer/filing/0001213900-25-027106.md","text":"https://secwatch.observer/filing/0001213900-25-027106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025027106/0001213900-25-027106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025027106/ea0236644-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T00:54:43.090970+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}